Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vyne Therapeutics Inc's Business Segments
Vyne Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Vyne Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - Q1 FY2026
- Royalty100%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Vyne Therapeutics Inc
Vyne Therapeutics Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutics for the treatment of various eye diseases. The company was founded in 2017 and is headquartered in Irvine, California.
Vyne Therapeutics is committed to developing innovative and effective treatments for eye diseases, using advanced technologies and scientific approaches to address unmet needs in ophthalmology. The company's primary focus is on treating dry eye disease, which affects millions of people worldwide.
The company has developed a pipeline of novel and differentiated drug candidates for the treatment of dry eye disease. These candidates are designed to address the underlying causes of the condition, such as inflammation and oxidative stress, rather than just addressing the symptoms.
One of the key products in Vyne Therapeutics' pipeline is VYN201, a first-in-class anti-inflammatory and anti-oxidant agent. The drug is designed to target multiple pathways involved in the inflammation and oxidative stress associated with dry eye disease, providing a more comprehensive treatment approach than currently available therapies.
Another product in the company's pipeline is VYN202, a small molecule that targets the TRPM8 ion channel. This channel is involved in regulating tear production, and VYN202 is designed to promote tear secretion and reduce dry eye symptoms.
In addition to its novel drug candidates, Vyne Therapeutics also has a strong focus on clinical development and regulatory affairs. The company's team of experienced researchers and clinicians are dedicated to conducting rigorous clinical trials and obtaining regulatory approvals for its products.
Overall, Vyne Therapeutics is a promising biopharmaceutical company that is focused on developing innovative and effective treatments for dry eye disease. With a strong pipeline, experienced team, and commitment to clinical development, the company is well-positioned for future success in the ophthalmology market.
Vyne Therapeutics is committed to developing innovative and effective treatments for eye diseases, using advanced technologies and scientific approaches to address unmet needs in ophthalmology. The company's primary focus is on treating dry eye disease, which affects millions of people worldwide.
The company has developed a pipeline of novel and differentiated drug candidates for the treatment of dry eye disease. These candidates are designed to address the underlying causes of the condition, such as inflammation and oxidative stress, rather than just addressing the symptoms.
One of the key products in Vyne Therapeutics' pipeline is VYN201, a first-in-class anti-inflammatory and anti-oxidant agent. The drug is designed to target multiple pathways involved in the inflammation and oxidative stress associated with dry eye disease, providing a more comprehensive treatment approach than currently available therapies.
Another product in the company's pipeline is VYN202, a small molecule that targets the TRPM8 ion channel. This channel is involved in regulating tear production, and VYN202 is designed to promote tear secretion and reduce dry eye symptoms.
In addition to its novel drug candidates, Vyne Therapeutics also has a strong focus on clinical development and regulatory affairs. The company's team of experienced researchers and clinicians are dedicated to conducting rigorous clinical trials and obtaining regulatory approvals for its products.
Overall, Vyne Therapeutics is a promising biopharmaceutical company that is focused on developing innovative and effective treatments for dry eye disease. With a strong pipeline, experienced team, and commitment to clinical development, the company is well-positioned for future success in the ophthalmology market.
Vyne Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of advanced therapies aimed at treating viral infections. The companys portfolio encompasses a variety of antiviral therapeutics that are designed to target an array of viral pathogens, including both RNA and DNA viruses. This strategic focus positions Vyne Therapeutics at the forefront of innovative solutions in the treatment of viral diseases.
Segments
Vyne Therapeutics offerings can be classified into two prominent segments based on the type of viruses they target: RNA viruses and DNA viruses.
1. RNA Viruses
The RNA virus segment is concentrated on the discovery, development, and commercialization of therapeutics that target RNA viruses. These include viruses responsible for seasonal flu, coronaviruses, and respiratory pathogens like RSV. The pipeline in this segment comprises several noteworthy candidates:
- Vyn-486: This is a small molecule inhibitor specifically being developed for the treatment of influenza A and B viruses. By inhibiting viral replication, Vyn-486 aims to reduce the severity and duration of influenza infections.
- Vyn-421: A promising antiviral drug candidate that targets coronaviruses, including SARS-CoV-2, the virus linked to COVID-19. The development of Vyn-421 reflects the urgent need for effective treatments in light of the global pandemic.
- Vyn-561: This dual-action antiviral drug candidate is designed to target both RSV and human metapneumovirus (hMPV). Given the significance of these respiratory viruses, especially in pediatric populations, Vyn-561 represents a multi-faceted approach toward combating viral respiratory infections.
DNA Viruses
The DNA virus segment focuses on creating therapies for the treatment of infections caused by DNA viruses. These include significant pathogens such as herpes simplex virus (HSV), cytomegalovirus (CMV), and human papillomavirus (HPV). The pipeline in this area features key products:
- Vyn-0504: This novel small molecule inhibitor is under development for the treatment of HSV-1 and HSV-2 infections. HSV is a common viral infection that can lead to various complications, and Vyn-0504 aims to address these challenges effectively.
- Vyn-1802: A biologic drug candidate that targets HPV-16, a strain associated with cervical cancer. The potential of Vyn-1802 lies in its ability to prevent the progression to cervical cancer, thereby impacting public health positively.
Products and Services
In addition to its therapeutic offerings for RNA and DNA viruses, Vyne Therapeutics provides several ancillary products and services that enhance its portfolio:
1. Viral Diagnostic Tests
Through Vyne Diagnostics, the company offers an array of rapid diagnostic tests that detect various viral infections, including influenza, COVID-19, and RSV. These tests are essential for timely diagnosis and treatment, particularly in outbreak scenarios.
Contract Research Services
Vyne Therapeutics engages in providing contract research services to other biopharmaceutical companies. These offerings encompass various areas of support, including preclinical testing, clinical trial management, and regulatory affairs consulting. By leveraging their expertise, Vyne Therapeutics aids other companies in navigating the complex landscape of drug development.
Intellectual Property Licensing
The company also engages in licensing its RNA and DNA antiviral therapeutics to other pharmaceutical entities. These licensing agreements serve as a revenue-generating stream for Vyne and facilitate collaborative development and commercialization efforts of new antiviral therapies.
Conclusion
Vyne Therapeutics Inc. presents a diverse and innovative suite of products and services aimed at combating viral infections. With dedicated pipelines targeting both RNA and DNA viruses, the company is positioned to address critical unmet medical needs in the field of virology. Their diagnostic capabilities, alongside contract research services and intellectual property licensing, further enhance their role in the biopharmaceutical landscape, ultimately contributing to the advancement of global health outcomes in infectious diseases.
Segments
Vyne Therapeutics offerings can be classified into two prominent segments based on the type of viruses they target: RNA viruses and DNA viruses.
1. RNA Viruses
The RNA virus segment is concentrated on the discovery, development, and commercialization of therapeutics that target RNA viruses. These include viruses responsible for seasonal flu, coronaviruses, and respiratory pathogens like RSV. The pipeline in this segment comprises several noteworthy candidates:
- Vyn-486: This is a small molecule inhibitor specifically being developed for the treatment of influenza A and B viruses. By inhibiting viral replication, Vyn-486 aims to reduce the severity and duration of influenza infections.
- Vyn-421: A promising antiviral drug candidate that targets coronaviruses, including SARS-CoV-2, the virus linked to COVID-19. The development of Vyn-421 reflects the urgent need for effective treatments in light of the global pandemic.
- Vyn-561: This dual-action antiviral drug candidate is designed to target both RSV and human metapneumovirus (hMPV). Given the significance of these respiratory viruses, especially in pediatric populations, Vyn-561 represents a multi-faceted approach toward combating viral respiratory infections.
DNA Viruses
The DNA virus segment focuses on creating therapies for the treatment of infections caused by DNA viruses. These include significant pathogens such as herpes simplex virus (HSV), cytomegalovirus (CMV), and human papillomavirus (HPV). The pipeline in this area features key products:
- Vyn-0504: This novel small molecule inhibitor is under development for the treatment of HSV-1 and HSV-2 infections. HSV is a common viral infection that can lead to various complications, and Vyn-0504 aims to address these challenges effectively.
- Vyn-1802: A biologic drug candidate that targets HPV-16, a strain associated with cervical cancer. The potential of Vyn-1802 lies in its ability to prevent the progression to cervical cancer, thereby impacting public health positively.
Products and Services
In addition to its therapeutic offerings for RNA and DNA viruses, Vyne Therapeutics provides several ancillary products and services that enhance its portfolio:
1. Viral Diagnostic Tests
Through Vyne Diagnostics, the company offers an array of rapid diagnostic tests that detect various viral infections, including influenza, COVID-19, and RSV. These tests are essential for timely diagnosis and treatment, particularly in outbreak scenarios.
Contract Research Services
Vyne Therapeutics engages in providing contract research services to other biopharmaceutical companies. These offerings encompass various areas of support, including preclinical testing, clinical trial management, and regulatory affairs consulting. By leveraging their expertise, Vyne Therapeutics aids other companies in navigating the complex landscape of drug development.
Intellectual Property Licensing
The company also engages in licensing its RNA and DNA antiviral therapeutics to other pharmaceutical entities. These licensing agreements serve as a revenue-generating stream for Vyne and facilitate collaborative development and commercialization efforts of new antiviral therapies.
Conclusion
Vyne Therapeutics Inc. presents a diverse and innovative suite of products and services aimed at combating viral infections. With dedicated pipelines targeting both RNA and DNA viruses, the company is positioned to address critical unmet medical needs in the field of virology. Their diagnostic capabilities, alongside contract research services and intellectual property licensing, further enhance their role in the biopharmaceutical landscape, ultimately contributing to the advancement of global health outcomes in infectious diseases.